New York, NY / ACCESSWIRE / November 18, 2014 / NeoStem, Inc. (NASDAQ: NBS) today published a new blog post on The Chairman's Blog, written by the Company's Chief Medical Officer, Dr. Douglas W. Losordo. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

Dr. Losordo further expanded on the latest findings from the Phase 2 PreSERVE AMI clinical trial. In his blog he wrote, "The six-month study results provides us with important information that will guide future clinical studies." Read the full blog post from Dr. Losordo on TheChairmansBlog.com (http://www.thechairmansblog.com/neostem/douglas-losordo/preserve-ami-phase-2-results/).

About NeoStem, Inc.

NeoStem is a biopharmaceutical company pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. The business includes the development of novel proprietary cell therapy products as well as a revenue-generating contract development and manufacturing service business. This combination has created an organization with unique capabilities for cost effective in-house product development and immediate revenue and cash flow generation. www.neostem.com

About TheChairmansBlog.com

TheChairmansBlog.com is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. www.thechairmansblog.com


SOURCE: TheChairmansBlog.com